Morbid obesity is not an independent predictor of graft failure or patient mortality after kidney transplantation. 2014

Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
The Transplant Center, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. Electronic address: pieloch@rwjuh.edu.

OBJECTIVE Obesity is often an absolute contraindication to kidney transplant, but an internal analysis of our center's recipients suggests that not all obese populations exhibit poor outcomes. We used national data to compare outcomes in select groups of morbidly obese and normal-weight recipients after kidney transplant. METHODS This study was a retrospective analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. METHODS The study sample consisted of 30,132 morbidly obese (body mass index [BMI] 35-40 kg/m(2)) and normal-weight (BMI 18.5-24.9 kg/m(2)) patients who underwent primary kidney-only transplantation between 2001 and 2006. METHODS Crude 3-year graft and patient survival rates of morbidly obese and normal-weight subgroups were evaluated. Logistic regression modeling compared 3-year graft failure and patient mortality in morbidly obese and normal-weight subgroups with opposite characteristics. Kaplan-Meier survival curves were created for 3-year graft and patient survival. Cox proportional hazard regression modeling was used to determine hazards for patient and graft mortality. RESULTS No differences in crude graft and patient survival rates were seen between normal weight and morbidly obese recipients who were African American, diabetic, and 50 to 80 years of age. Morbidly obese recipients who were nondialysis dependent, nondiabetic, had good functional status, and received living-donor transplants had significantly lower 3-year graft failure and patient mortality risk compared with normal-weight recipients who were dialysis dependent, diabetic, had poor functional status, and received a deceased-donor transplant, respectively (P < .01). Morbidly obese recipients have significantly lower graft and patient survival curves compared with normal-weight recipients; however, multivariate regression analysis reveals that morbid obesity is not an independent predictor of graft failure or patient mortality. CONCLUSIONS Morbid obesity is not independently associated with graft failure or patient mortality; therefore, it should not be used as a contraindication to kidney transplantation.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009767 Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2. Morbid Obesity,Obesity, Severe,Morbid Obesities,Obesities, Morbid,Obesities, Severe,Severe Obesities,Severe Obesity
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
January 2020, American journal of nephrology,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
July 2009, Transplantation,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
January 2022, Frontiers in immunology,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
May 2004, American journal of surgery,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
January 2023, Frontiers in immunology,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
December 2015, The Journal of arthroplasty,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
February 2019, Transplantation,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
December 2018, Scientific reports,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
September 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Daniel Pieloch, and Viktor Dombrovskiy, and Adena J Osband, and Jonathan Lebowitz, and David A Laskow
February 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Copied contents to your clipboard!